Search Results
Sep 08, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.93 Million Tokens, and Total Crypto and Total Cash Holdings of $15.7 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of ETHNORWALK,
More news about: Bitmine Immersion Technologies, Inc.
Sep 08, 2026, 08:30 ET Bitmine Immersion Technologies (BMNR) Announces ETH Holdings Reach 5.93 Million Tokens, and Total Crypto and Total Cash Holdings of $15.7 Billion
Bitmine remains supported by a premier group of institutional investors including ARK's Cathie Wood, MOZAYYX, Founders Fund, Bill Miller III, Pantera, Kraken, DCG, Galaxy Digital and personal investor Thomas "Tom" Lee to support Bitmine's goal of acquiring 5% of
More news about: Bitmine Immersion Technologies, Inc.
Sep 08, 2026, 08:20 ET Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase II/III adaptive seamless design clinical trial of AC-201 tablets (Fosun development code: FXS5626) for the treatment of non-segmental vitiligo. Fosun Pharma
More news about: Accro Bioscience (Suzhou) Limited
Sep 08, 2026, 08:15 ET 禮邦醫藥 AP308 治療 IgA 腎病的新藥臨床試驗申請獲美國 FDA 批准
禮邦醫藥（09637.HK）是一家專注於腎臟疾病及相關慢性病領域的生物醫藥公司。圍繞慢性腎臟病（CKD）不同階段及其併發症的臨床需求，公司構建了腎病適應症覆蓋廣泛的創新產品組合，並形成涵蓋研發、生產及商業化的一體化平台，致力於為全球腎臟疾病患者帶來更優的治療方案。目前，公司已擁有 7 款在研候選產品及 1 款商業化產品（美信羅®），其中 AP301、AP306 及 AP303 三款在研產品已進入臨床階段，分別處於臨床 III 期、II 期及 I 期，AP308 的新藥臨床試驗申請亦已獲美國 FDA 批准；其中 AP301 的中國關鍵性III 期臨床試驗已完成，新藥上市申請已獲國家藥品監督管理局受理，全球多區域臨床試驗（MRCT）正在進行。整體產品組合覆蓋慢性腎臟病及其併發症的多個適應症，包括高磷血症、腎性貧血、IgA
More news about: 禮邦醫藥
Sep 08, 2026, 08:05 ET Alebund Pharmaceuticals Announces FDA Clearance of IND Application for AP308 for the Treatment of IgA Nephropathy
investigational drug candidates and one commercialized product, Mircera®. Three of the candidates are at the clinical stage: AP301 (China pivotal Phase III trial completed, NDA accepted for review by the NMPA, global MRCT ongoing), AP306 (Phase II) and AP303 (Phase I), and the IND application for AP308 has
More news about: Alebund Pharmaceuticals
Sep 08, 2026, 08:00 ET Notice of Pendency and Proposed Settlement of Class Action Announced in Edwards Lifesciences Securities Litigation
SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION AND PROPOSED SETTLEMENT; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSESTO: All persons or entities who purchased or otherwise acquired Edwards Lifesciences
More news about: Kroll Settlement Administration LLC
Sep 08, 2026, 08:00 ET Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
safety data and topline results for the Phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, (iv) statements about our clinical
More news about: Azitra, Inc.
Sep 08, 2026, 07:55 ET Sempra Celebrates Next Chapter of Growth with NYSE Opening Bell
to, as applicable, (i) being able to reach a positive final investment decision, (ii) negotiating pricing and other terms in definitive contracts, (iii) completing construction projects or other transactions on schedule and budget, (iv) realizing anticipated benefits from any of these efforts if completed,
More news about: Sempra
Sep 08, 2026, 07:26 ET Celebrate Organic Month at Natural Grocers® With Exclusive Savings, Education, Freebies, Sweepstakes, and More
Void where prohibited by law.[iii] NO PURCHASE NECESSARY. A PURCHASE WILL NOT INCREASE YOUR CHANCES OF WINNING. Open only to legal residents, 18 years or older, of the following
More news about: Natural Grocers by Vitamin Cottage, Inc.
Sep 08, 2026, 06:35 ET INVESTOR DEADLINE: UWM Holdings Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before October 13, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - UWMC
mortgage servicing rights to take a major hedge position; (ii) UWM over-hedged itself in anticipation of the Two Harbors Investment Corp. transaction; (iii) UWM's purported efforts to balance its risk in fact created an excess hedging risk; and (iv) that, as a result of the foregoing, defendants' positive
More news about: Robbins Geller Rudman & Dowd LLP
Sep 08, 2026, 06:00 ET Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend
referral and service fees, (ii) an increase of RMB21.4 million in short message service (SMS) costs for new user onboarding and authentication processes, (iii) an increase of RMB11.2 million in personnel costs, and (iv) an increase of RMB8.2 million in the costs for the digital clinical trial solution consultants
More news about: Waterdrop Inc.
Sep 08, 2026, 03:19 ET Brightstar Lottery PLC Announces Tender Offer and a Benchmark Offering of Senior Secured Notes Due 2032
purchase in connection with the Offer and accrued and unpaid interest thereon, (ii) to repay utilizations under its senior revolving credit facilities and (iii) to pay fees and expenses incurred in connection with the Offer and the Offering.The purpose of the Offer and the Offering is to extend the weighted
More news about: Brightstar Lottery PLC
Sep 08, 2026, 00:36 ET Sentimen Rekrutmen Menguat di Asia Pasifik dan Timur Tengah, NEO Capai +33% pada Triwulan IV-2026: Survei ManpowerGroup
musiman untuk Triwulan IV-2026 di Asia Pasifik dan Timur Tengah (APME) mencapai +33%, meningkat lima poin dari Triwulan III-2026 dan empat poin dibandingkan periode yang sama pada tahun lalu.Sektor Informasi mencatat NEO terkuat pada Triwulan IV-2026 sebesar +42%,
More news about: ManpowerGroup
Sep 07, 2026, 17:00 ET WaFd, Inc. Enters into a $3.9 Billion Reverse Merger Transaction with EverBank Financial Corp
instituted against WaFd or its directors or officers related to the proposed transaction or the definitive merger agreement between WaFd and EverBank; (iii) the timing and completion of the transaction, including the possibility that the proposed transaction will not close when expected or at all because
More news about: WaFd, Inc. and EverBank Financial Corp
Sep 07, 2026, 16:10 ET Lion Announces Plan to Implement ADS Ratio Change
offers a wide spectrum of products and services, including (i) total return service (TRS) trading, (ii) contract-for-difference (CFD) trading, and (iii) Over-the-counter (OTC) stock options trading. Additional information may be found at http://ir.liongrouphl.com.Forward-Looking
More news about: Lion Group Holding Ltd.
Sep 07, 2026, 15:45 ET Datavault AI, Inc. (DVLT) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Plaintiff and other Class members, as alleged herein; (ii) artificially inflate and maintain the market price of Datavault AI securities; and (iii) cause Plaintiff and other members of the Class to purchase or otherwise acquire Datavault AI securities and options at artificially inflated prices.
More news about: Glancy Prongay Wolke & Rotter LLP
Sep 07, 2026, 10:05 ET Summary Notice to Stockholders of Supernova Partners Acquisition Company, Inc. as of August 27, 2021
should be finally appointed as Class representatives for the Class and Plaintiff's Counsel should be finally appointed as Class counsel for the Class; (iii) determine whether the proposed Settlement on the terms and conditions provided for in the Stipulation should be approved as fair, reasonable, and adequate
More news about: Levi & Korsinsky, LLP
Sep 07, 2026, 06:22 ET AtomVie Global Radiopharma feiert die große Eröffnung seiner neuen, hochmodernen Produktionsstätte für Radiopharmaka in Hamilton, Ontario
Dienstleistungen in Kombination mit einer spezialisierten Infrastruktur für die Entwicklung von Radiopharmazeutika von klinischen Studien der Phasen I bis III bis hin zur Markteinführung anbietet. AtomVie betreut derzeit internationale Kunden, die klinische Studien in über 28 Ländern weltweit durchführen. Weitere
More news about: AtomVie Global Radiopharma Inc.
Sep 07, 2026, 06:15 ET AtomVie Global Radiopharma célèbre l'inauguration officielle de sa nouvelle usine de fabrication de produits radiopharmaceutiques à la pointe de la technologie à Hamilton, en Ontario
associée à une infrastructure spécialisée dans le développement de produits radiopharmaceutiques, depuis les essais cliniques de phase I jusqu'à la phase III, puis à la commercialisation. AtomVie travaille actuellement avec des clients internationaux qui mènent des études cliniques dans plus de 28 pays à travers
More news about: AtomVie Global Radiopharma Inc.
Sep 07, 2026, 05:42 ET Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks
this progress is rentosertib (ISM001-055), the world's first drug candidate discovered and developed using generative AI, which has advanced to a Phase III trial evaluating for idiopathic pulmonary fibrosis (IPF). In addition, Insilico Medicine launched a comprehensive set of benchmarks that allow foundation
More news about: Insilico Medicine
Sep 06, 2026, 23:02 ET Bitmine Immersion Technologies（BMNR）宣佈 ETH 持有量達 590 萬枚，加密資產及現金持有總額達 156 億美元
億美元，包括 590 萬枚 ETH、總值 5.41 億美元的現金及有價證券，以及其他加密資產Bitmine 仍然得到頂級機構投資者（包括 ARK 的 Cathie Wood、MOZAYYX、Founders Fund、Bill Miller III、Pantera、Kraken、DCG、Galaxy Digital 和個人投資者 Thomas "Tom" Lee）支持，從而支援 Bitmine 收購 5% ETH 的目標康涅狄格州諾沃克
More news about: Bitmine Immersion Technologies, Inc.
Sep 06, 2026, 20:46 ET Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction
of complex soft tissue reconstruction procedures in a highly challenging real-world patient population. Approximately 59% of patients were ASA Class III or IV, indicating significant underlying systemic disease. In addition, 35% had diabetes, 30% had vascular disease and 23% used nicotine. The defects
More news about: Aroa Biosurgery
Sep 06, 2026, 20:01 ET Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
treatment of COPD and completed dosing of the first patients. Meanwhile, initial readouts from the Phase II/III POLARIS study in asthma are expected in the second half of 2026, with the first Phase III study of HBM9378 in asthma is expected to begin in the fourth quarter of 2026.Additionally, continued
More news about: Harbour BioMed
Sep 06, 2026, 14:39 ET Huawei präsentiert Flaggschiff-Produkte der nächsten Generation bei der globalen Innovationsveranstaltung „Chase the Wild" in München
Behandlungen herangezogen werden.[iii] Diese Funktion ist nicht für medizinische Zwecke bestimmt. Die Ergebnisse dienen lediglich als Anhaltspunkt und sollten nicht als Grundlage für medizinische
More news about: Huawei
Sep 06, 2026, 14:36 ET Huawei presenta sus productos insignia de última generación en el evento "Chase the Wild" en Múnich
diagnóstico o tratamiento médico.[iii] Esta función no está destinada a uso médico. Los resultados son solo de referencia y no deben utilizarse como base para un diagnóstico o tratamiento
More news about: Huawei